Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction
Ignacio Cruz‐González(Instituto de Investigación Biomédica de Salamanca), José M. López‐Novoa(Universidad de Salamanca), Andrew Maree(Harvard University), Pedro Pabón, Pedro L. Sánchez(Instituto de Investigación Biomédica de Salamanca), María Sánchez Ledesma(Complejo Hospitalario de Salamanca), Alicia Rodríguez‐Barbero(Universidad de Salamanca), Miguel Pericacho(Universidad de Salamanca), Ángel Sánchez‐Rodríguez(Universidad de Salamanca), Javier Jiménez‐Candil(Instituto de Investigación Biomédica de Salamanca), Francisco Martín‐Herrero(Universidad de Salamanca), Javier Martín‐Moreiras(Complejo Hospitalario de Salamanca), Víctor Ramírez(Universidad de Salamanca), Cándido Martín‐Luengo(Universidad de Salamanca)
Cited by 51
Related Papers
Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study
|European Heart Journal|2017|295
Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology
|Circulation Arrhythmia and Electrophysiology|2019|286
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia
|Journal of the American College of Cardiology|2022|175
L- and S-endoglin differentially modulate TGFβ1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts
|Journal of Cell Science|2008|117
Continuously Evaluating Performance in Deceased Donation: The Spanish Quality Assurance Program
|American Journal of Transplantation|2012|93